Benedicto Crespo Facorro
HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA
Sant Pau Biomedical Research Institute
Spain
Biography
Benedicto Crespo-Facorro is associate Professor of Psychiatry and deputy head of the Department of Medicine and Psychiatry, University of Cantabria, Santander. He trained in Psychiatry at the Hospital Clinico San Carlos, Complutense University, Madrid and after his clinical training was awarded by Spanish Institute of Health Carlos III a two-year research Fellowship in schizophrenia research at the Mental Health Clinical Research Center, University of Iowa, USA. He is currently Director of Cantabria Psychoses First Episode Service (PAFIP) and principal Investigator of the research group CIBERSAM G26. He is on the editorial board of European, American and Asiatic journals. Areas of interest include the clinical, cognitive and biological basis of schizophrenia, in particular the study of imaging genetics, metabolomic and genomics of non-affective psychoses in early phases of illness. Treatment studies focus on treatment effectiveness and safety of antipsychotics, and aspects of medical and mental comorbidity of schizophrenia. He has received several scientific awards: the annual Young Investigator Award from the American Neuropsychiatric Association (ANPA, 1997), Young Investigator Award of the International Congress on Schizophrenia Research (ICOSR, 2001), Reference Researcher in Psychiatry Award from de Sociedad Española de Psquiatría Biológica (SEPB, 2006) and Bank of Sabadell ¨National Award of Research in Biomedicine” (2007).Over the period 2000-2013, his group published over 140 papers on MEDLINE in leading psychiatric, neuroscience and general medical journals, h factor 32.
Research Interest
Psychiatry
Publications
-
Morlán-Coarasa MJ1, Arias-Loste MT2, Ortiz-GarcÃa de la Foz V3, MartÃnez-GarcÃa O3, Alonso-MartÃn C2, Crespo J2, Romero-Gómez M4, Fábrega E2, Crespo-Facorro B5. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology (Berl). 2016 Dec;233(23-24):3947-3952.